TG Therapeutics Inc. (NASDAQ:TGTX) finished Thursday with an addition of $0.02 to close at $9.70, an upside of 0.21 percent. An average of 6,304,360 shares of common stock have been traded in the last five days. There was a fall of -$1.50 in the past week, and it reached a new high 30 times over the past 12 months. The last 20 days have seen an average of 6,919,015 shares traded, while the 50-day average volume stands at 4,944,252.
TGTX stock has decreased by -61.90% in the last month. The company shares reached their 1-month lowest point of $9.51 on 08/10/23. With the stock rallying to its 52-week high on 05/04/23, shares of the company touched a low of $4.86 and a high of $35.67 in 52 weeks. It has reached a new high 22 times so far this year and lost -18.01% or -$2.13 in price. In spite of this, the price is down -72.81% from the 52-week high.
Insider Transactions
TGTX stock investors should be aware that TG Therapeutics Inc. (TGTX) stock had its last reported insider trading activity 49 days ago on Jun 23. In this transaction, the insider spent $814,538. Chief Financial Officer, Power Sean A, disposed of 73,647 shares at a price of $26.70 on Jun 02. The insider now owns more than $1,966,375 worth of shares. Prior to that, Director Charney Laurence N went on to Sale 30,000 shares at $11.10 each on Jan 04. An amount of $333,000 was transacted.
Valuation Metrics
TG Therapeutics Inc. (TGTX) stock’s beta is 2.12. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 62.88, the price-to-book (PB) ratio at 48.50.
Financial Health
The quick ratio of TG Therapeutics Inc. for the three months ended June 29 was 2.50, and the current ratio was 2.90, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 3.52 and a total debt to equity ratio of 0.00 for the quarter ending June 29. TG Therapeutics Inc.’s EBITDA margin for the year ending June 29 is -6905.71%. Its gross profit as reported stood at $2.52 million compared to revenue of $2.79 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, TG Therapeutics Inc.’s return on assets was -92.20%.
Earnings Surprise
For the three-month period that ended June 29, TG Therapeutics Inc. had $47.9 million in cash and short-term investments compared to $97.7 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$47.61 million in the quarter, while revenues of -$39.23 million were grew 14.91%. The analyst consensus anticipated TG Therapeutics Inc.’s latest quarter earnings to come in at -$0.25 per share, but it turned out to be -$0.34, a -36.00% surprise. For the quarter, EBITDA amounted to -$44.14 million. Shareholders own equity worth $150.98 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at TG Therapeutics Inc. (TGTX) price momentum. RSI 9-day as of the close on 10 August was 15.53%, suggesting the stock is oversold, with historical volatility in this time frame at 336.46%.
As of today, TGTX’s price is $9.97 -13.39% or -$1.50 from its 5-day moving average. TGTX is currently trading -55.40% lower than its 20-day SMA and -34.42% lower than its 100-day SMA. However, the stock’s current price level is -61.95% below the SMA50 and +86.18% above the SMA200.
The stochastic %K and %D were 1.36% and 2.76%, respectively, and the average true range (ATR) was 1.37. With the 14-day stochastic at 1.66% and the average true range at 1.46, the RSI (14) stands at 19.57%. The stock has reached -1.74 on the 9-day MACD Oscillator while the 14-day reading was at -4.82.
Analyst Ratings
Goldman upgraded TG Therapeutics Inc. (NASDAQ: TGTX) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as a Sell. The consensus rating for TG Therapeutics Inc. (TGTX) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell TGTX, while 1 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 7 others rate it as a “buy”.
What is TGTX’s price target for the next 12 months?
Analysts predict a range of price targets between $6.00 and $41.00, with a median target of $32.00. Taking a look at these predictions, the average price target given by analysts for TG Therapeutics Inc. (TGTX) stock is $28.94.
